Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Hoelscher

Optometrist Dallas, TX Doctor of Optometry

NPI 1508874520 CMS profile 203956

2801 Lemmon Ave Ste 400, Dallas, TX 75204

Open in the dashboard

General payments

$17,769

185 records reported · program years 2019–2025

Research payments

$16

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$26,440 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Amanda Hoelscher of Dallas, TX is reported in the CMS Open Payments database as having received $17,769 across 185 general payments and $16 in research payments paid to them. Separately, studies naming them as principal investigator received $26,440 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,311 43
2024 General $4,915 47
2023 General $8,136 35
2022 General $1,163 24
2021 General $193 10
2021 Research $16 1
2020 General $381 16
2019 General $670 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Hoelscher
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Amanda Hoelscher were reported at $2,311. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Amanda Hoelscher Optometrist median Middle half National median
2019 $670 $159 $67–$371 $163
2020 $381 $72 $29–$165 $114
2021 $193 $125 $46–$292 $132
2022 $1,163 $162 $66–$374 $149
2023 $8,136 $177 $72–$406 $160
2024 $4,915 $188 $77–$427 $164
2025 $2,311 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lumenis BE inc $8,018 2 payments
  2. RxSight Inc $2,754 6 payments
  3. Bausch & Lomb Americas Inc. $1,650 17 payments
  4. Johnson & Johnson Vision Care, Inc. $856 19 payments
  5. Johnson & Johnson Surgical Vision, Inc. $779 8 payments
  6. AbbVie, Inc. $601 28 payments
  7. Novartis Pharmaceuticals Corporation $496 16 payments
  8. Alcon Vision LLC $406 17 payments
  9. Harrow Eye, LLC $305 6 payments
  10. Sun Pharmaceutical Industries Inc. $296 11 payments
  11. Other $1,608 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,366 181 payments
  2. Consulting Fee $3,368 2 payments
  3. Honoraria $26 1 payment
  4. Education $10 1 payment
Products named General payments · program years 2019–2025
  1. optilight $4,500 1 payment
  2. M22 $3,518 1 payment
  3. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $2,608 3 payments
  4. RXSIGHT CONTACT LENS $2,608 3 payments
  5. RXSIGHT INJECTOR CARTRIDGE $2,608 3 payments
  6. RXSIGHT INJECTOR HANDPIECE $2,608 3 payments
  7. RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL) $2,583 2 payments
  8. MIEBO $972 4 payments
  9. Acuvue $648 14 payments
  10. Tecnis Simplicity $497 5 payments
  11. Other $6,095 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. RxSight Inc $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

911

Median for Optometry: 120

Drug cost

$229,066

Median for Optometry: $8,864

Branded share of claims

35.6%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xiidra Lifitegrast Brand 48 $74,230
Restasis Cyclosporine Brand 39 $58,349
Xdemvy Lotilaner Brand 20 $37,677
Miebo Perfluorohexyloctane/Pf Brand 27 $22,503
Combigan Brimonidine Tartrate/Timolol Brand 26 $9,024
Lumigan Bimatoprost Brand 11 $5,904
Ilevro Nepafenac Brand 11 $4,014
Latanoprost Generic 324 $3,455
Prednisolone Acetate Generic 122 $3,361
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 16 $3,020

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$91,914

Medicare's payments for the services billed

Medicare patients

715

Average age 74

Services billed

1,544

416 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 46%
Diabetes 27%
Ischemic heart disease 23%
Chronic kidney disease 21%
Depression 18%
Cancer 17%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LUMIGAN
  • AbbVie, Inc. $173
$173 11 —
VEVYE
  • Harrow Eye, LLC $149
$149 — —
VELSIPITY
  • PFIZER INC. $130
$130 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $106
$106 48 —
MIEBO
  • Bausch & Lomb Americas Inc. $62
$62 27 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record